Clinical Cancer Research Meeting Calendar AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Curiel, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Curiel, D. T.
Clinical Cancer Research Vol. 6, 3395-3399, September 2000
© 2000 American Association for Cancer Research


Minireview

The Development of Conditionally Replicative Adenoviruses for Cancer Therapy1

David T. Curiel2

University of Alabama at Birmingham, Birmingham, Alabama 35294-3300

Replicative viral agents represent a novel approach for treating neoplastic disease. Tumor cell killing by the viral agent is achieved by direct consequence of the viral replication. Relative sparing of nontumor is, however, required to provide a therapeutic index of utility for cancer treatment. To this end, an ideal viral agent would, thus, possess several logical attributes, including stability and efficiency for infection and lateral spread in vivo, a preference for replication in tumor versus nontumor cells, and the capability of avoiding early detection—and eradication—by the immune system. To date, none of the agents has exhibited optimal characteristics with regard to the aforementioned attributes. Adenovirus, however, has lent itself to a process of extensive engineering that is dealing with each and every one of the major requirements and that is realizing its clinical potential. An advanced understanding of the cancer phenotype, as well as achievements in functionally exploiting viral plasticity, predicate the design and realization of conditionally replicative adenoviral agents with improved characteristics for cancer therapy.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
X. Huang, L. Zhuang, Y. Cao, Q. Gao, Z. Han, D. Tang, H. Xing, W. Wang, Y. Lu, G. Xu, et al.
Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration
Mol. Cancer Ther., June 1, 2008; 7(6): 1624 - 1632.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Luo, Q. Xia, R. Zhang, C. Lv, W. Zhang, Y. Wang, Q. Cui, L. Liu, R. Cai, and C. Qian
Treatment of Cancer with a Novel Dual-Targeted Conditionally Replicative Adenovirus Armed with mda-7/IL-24 Gene
Clin. Cancer Res., April 15, 2008; 14(8): 2450 - 2457.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Wakayama, M. Abei, R. Kawashima, E. Seo, K. Fukuda, H. Ugai, T. Murata, N. Tanaka, I. Hyodo, H. Hamada, et al.
E1A, E1B Double-Restricted Adenovirus with RGD-Fiber Modification Exhibits Enhanced Oncolysis for CAR-Deficient Biliary Cancers
Clin. Cancer Res., May 15, 2007; 13(10): 3043 - 3050.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Q. Zhang, G. Chen, L. Peng, X. Wang, Y. Yang, C. Liu, W. Shi, C. Su, H. Wu, X. Liu, et al.
Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Clin. Cancer Res., November 1, 2006; 12(21): 6523 - 6531.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
D. T. Curiel
Next Generation CRAds for Virotherapy of Cancer
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 141 - 144.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. T. Rein, M. Breidenbach, T. O. Kirby, T. Han, G. P. Siegal, G. J. Bauerschmitz, M. Wang, D. M. Nettelbeck, Y. Tsuruta, M. Yamamoto, et al.
A Fiber-Modified, Secretory Leukoprotease Inhibitor Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer
Clin. Cancer Res., February 1, 2005; 11(3): 1327 - 1335.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Seo, M. Abei, M. Wakayama, K. Fukuda, H. Ugai, T. Murata, T. Todoroki, Y. Matsuzaki, N. Tanaka, H. Hamada, et al.
Effective Gene Therapy of Biliary Tract Cancers by a Conditionally Replicative Adenovirus Expressing Uracil Phosphoribosyltransferase: Significance of Timing of 5-Fluorouracil Administration
Cancer Res., January 15, 2005; 65(2): 546 - 552.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. O. Kirby, A. Rivera, D. Rein, M. Wang, I. Ulasov, M. Breidenbach, M. Kataram, J. L. Contreras, C. Krumdieck, M. Yamamoto, et al.
A Novel Ex vivo Model System for Evaluation of Conditionally Replicative Adenoviruses Therapeutic Efficacy and Toxicity
Clin. Cancer Res., December 15, 2004; 10(24): 8697 - 8703.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Mitrofanova, R. Unfer, N. Vahanian, W. Daniels, E. Roberson, T. Seregina, P. Seth, and C. Link Jr.
Rat Sodium Iodide Symporter for Radioiodide Therapy of Cancer
Clin. Cancer Res., October 15, 2004; 10(20): 6969 - 6976.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Shirakawa, K. Hamada, Z. Zhang, H. Okada, M. Tagawa, S. Kamidono, M. Kawabata, and A. Gotoh
A Cox-2 Promoter-Based Replication-Selective Adenoviral Vector to Target the Cox-2-Expressing Human Bladder Cancer Cells
Clin. Cancer Res., July 1, 2004; 10(13): 4342 - 4348.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Davydova, L. P. Le, T. Gavrikova, M. Wang, V. Krasnykh, and M. Yamamoto
Infectivity-Enhanced Cyclooxygenase-2-Based Conditionally Replicative Adenoviruses for Esophageal Adenocarcinoma Treatment
Cancer Res., June 15, 2004; 64(12): 4319 - 4327.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
N. S. Banerjee, A. A. Rivera, M. Wang, L. T. Chow, T. R. Broker, D. T. Curiel, and D. M. Nettelbeck
Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures
Mol. Cancer Ther., April 1, 2004; 3(4): 437 - 449.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Fukuda, M. Abei, H. Ugai, E. Seo, M. Wakayama, T. Murata, T. Todoroki, N. Tanaka, H. Hamada, and K. K. Yokoyama
E1A, E1B Double-restricted Adenovirus for Oncolytic Gene Therapy of Gallbladder Cancer
Cancer Res., August 1, 2003; 63(15): 4434 - 4440.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Wirth, L. Zender, B. Schulte, B. Mundt, R. Plentz, K. L. Rudolph, M. Manns, S. Kubicka, and F. Kuhnel
A Telomerase-dependent Conditionally Replicating Adenovirus for Selective Treatment of Cancer
Cancer Res., June 15, 2003; 63(12): 3181 - 3188.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Suzuki, R. Alemany, M. Yamamoto, and D. T. Curiel
The Presence of the Adenovirus E3 Region Improves the Oncolytic Potency of Conditionally Replicative Adenoviruses
Clin. Cancer Res., November 1, 2002; 8(11): 3348 - 3359.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. M. Nettelbeck, A. A. Rivera, C. Balague, R. Alemany, and D. T. Curiel
Novel Oncolytic Adenoviruses Targeted to Melanoma: Specific Viral Replication and Cytolysis by Expression of E1A Mutants from the Tyrosinase Enhancer/Promoter
Cancer Res., August 15, 2002; 62(16): 4663 - 4670.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Adachi, P. N. Reynolds, M. Yamamoto, M. Wang, K. Takayama, S. Matsubara, T. Muramatsu, and D. T. Curiel
A Midkine Promoter-based Conditionally Replicative Adenovirus for Treatment of Pediatric Solid Tumors and Bone Marrow Tumor Purging
Cancer Res., November 1, 2001; 61(21): 7882 - 7888.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Xu and H. L. McLeod
Strategies for Enzyme/Prodrug Cancer Therapy
Clin. Cancer Res., November 1, 2001; 7(11): 3314 - 3324.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. L. DeWeese, H. van der Poel, S. Li, B. Mikhak, R. Drew, M. Goemann, U. Hamper, R. DeJong, N. Detorie, R. Rodriguez, et al.
A Phase I Trial of CV706, a Replication-competent, PSA Selective Oncolytic Adenovirus, for the Treatment of Locally Recurrent Prostate Cancer following Radiation Therapy
Cancer Res., October 1, 2001; 61(20): 7464 - 7472.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Ichikawa and E. A. Chiocca
Comparative Analyses of Transgene Delivery and Expression in Tumors Inoculated with a Replication-conditional or -defective Viral Vector
Cancer Res., July 1, 2001; 61(14): 5336 - 5339.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. P. Cripe, E. J. Dunphy, A. D. Holub, A. Saini, N. H. Vasi, Y. Y. Mahller, M. H. Collins, J. D. Snyder, V. Krasnykh, D. T. Curiel, et al.
Fiber Knob Modifications Overcome Low, Heterogeneous Expression of the Coxsackievirus-Adenovirus Receptor That Limits Adenovirus Gene Transfer and Oncolysis for Human Rhabdomyosarcoma Cells
Cancer Res., April 1, 2001; 61(7): 2953 - 2960.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
J. T. Douglas, M. Kim, L. A. Sumerel, D. E. Carey, and D. T. Curiel
Efficient Oncolysis by a Replicating Adenovirus (Ad) in Vivo Is Critically Dependent on Tumor Expression of Primary Ad Receptors
Cancer Res., February 1, 2001; 61(3): 813 - 817.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.